Quando uma patente expira, não se trata apenas de uma mudança jurídica — trata-se de uma redistribuição de poder sobre quem pode acessar o alívio que a medicina promete. No Brasil, a aprovação do Ozivy pela Anvisa em maio de 2026 marca o fim do monopólio da Novo Nordisk sobre a semaglutida, abrindo caminho para que fabricantes nacionais disputem um mercado que combina necessidade médica genuína, fenômeno cultural e bilhões em receita. A EMS tornou-se a primeira empresa brasileira a cruzar esse limiar regulatório, sinalizando que o acesso a tratamentos para diabetes e obesidade pode, com o temp
Brasil 247
· May 26, 2026
· health
· 2 min read
High
Sourcing: Verified
Anvisa aprova Ozivy, primeira semaglutida nacional após patente expirar
◉
Health & Medicine
2792 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
Related Coverage
O POVO · Aug 23
Dia D mobiliza Fortaleza com multivacinação e mutirão bucal em 264 locais
Fortaleza realizou mobilização massiva de imunização com 3 mil profissionais em 264 locais, incluindo multivacinação, mu…
Folha de S.Paulo · Aug 23 Tratar apneia do sono pode reduzir pressão arterial em hipertensosEstudo brasileiro demonstra que tratar apneia obstrutiva do sono contribui para reduzir hipertensão resistente, mesmo em…
Rádio Pampa · Aug 23 Duas em cada três pessoas com Alzheimer são mulheres; sintomas podem começar aos 45Pesquisa mostra que duas em cada três pessoas com Alzheimer são mulheres, com sintomas podendo começar aos 45 anos devid…
Rádio Pampa · Aug 23 Dieta rica em vegetais reduz risco de doença renal crônica, aponta estudoEstudo com 179.508 participantes mostra que dieta rica em vegetais, frutas e grãos integrais reduz risco de doença renal…
Bias & Framing
⚖
Article presents Anvisa's approval of domestic semaglutide as market competition news with optimistic framing about price reduction and access expansion.
Bias Direction
center-left
Confidence
MED
Pro-competition/pro-consumer framing emphasizing benefits of market entry and price pressure, with positive language around regulatory approval and access expansion. Frames patent expiration as opening opportunity rather than discussing innovation incentives.
canetas emagrecedoras (weight-loss pens) - colloquial, sensationalized term
disputa pelo mercado (market dispute) - adversarial framing
segmento bilionário (billion-dollar segment) - emphasizes market size/profit
forte procura (strong demand) - implies popularity/desirability
expectativa é que...os preços possam cair (expectation that prices may fall) - optimistic projection
Novo Nordisk's position on generic competition and innovation concerns
Potential concerns about quality/safety of new manufacturers
Cost of regulatory approval process for domestic manufacturers
Intellectual property or innovation incentive discussion
Patient access barriers beyond price (distribution, insurance coverage)
Timeline realism for actual price reductions
Geopolitical Impact
🌎
Brazil's approval of domestic semaglutide (Ozivy) after Novo Nordisk's patent expiration signals market liberalization in GLP-1 drugs, potentially reducing prices and expanding access while reshaping pharmaceutical competition in Latin America's largest economy.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Global pharmaceutical markets
Shift from Novo Nordisk's monopoly to competitive market; strengthens Brazilian pharmaceutical sovereignty and domestic industry (EMS); reduces dependency on Danish multinational; may inspire similar generic/biosimilar approvals across Latin America; positions Brazil as regional pharmaceutical hub for GLP-1 production.
Similar to India's generic drug revolution post-TRIPS flexibilities, enabling domestic manufacturers to capture markets after patent expiration and establish regional pharmaceutical leadership.
Economic Lens
📈
Brazil's approval of EMS's domestic semaglutide (Ozivy) post-patent expiration introduces competition to the GLP-1 market, likely reducing prices and expanding access to diabetes/obesity treatments.
Market Signal
mixed
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Medical Services
Consumer Health Products
Public Health Systems
Consumers and patients will benefit from lower medication costs as competition increases, improving access to semaglutide treatments for diabetes and obesity. However, availability may be initially limited as new competitors scale production.
Regulatory approval of biosimilar pathways encourages domestic pharmaceutical development and reduces dependence on foreign monopolies. Government may consider price regulation or subsidy programs to accelerate public access through the health system (SUS).